The U.S. Supreme Court denied Agilent Technologies’ request to revisit CRISPR patent invalidation in its dispute with Synthego. The decision leaves intact a June 2025 Federal Circuit ruling that upheld PTAB findings deeming certain Agilent guide-RNA modification claims unpatentable. For the gene-editing ecosystem, the outcome is a legal clean-up that lowers remaining barriers tied to those specific chemical gRNA modifications, potentially affecting licensing and operational freedom for researchers developing CRISPR-enabled therapeutics and platforms.